L Page 272 and 273: Langston WJ, Burt GR, Chesman BS, a Page 274 and 275: Latch DE, Packer JL, Arnold WA, and Page 276 and 277: molecularly imprinted polymer." Wat Page 278 and 279: Lee H-B, Peart TE, and Svoboda ML
Target Oncol
Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG, et al
Start with a lower concentration (around 10%), patch-test before full use, and introduce products gradually
Bn cnh , nng ca loi thuc ny cng c kh nng b suy gim dn theo tui
328 With the success of Alnylam in GalNAc, other companies have focused on RNA therapy and developed their delivery systems